States probe Eli Lilly over insulin prices

Aug 05, 2019

Eli Lilly has been hit with a subpoena from the New York Attorney General’s Office over the pricing and sales of its insulin treatments.

The drugmaker disclosed the probe a recent filing with the Securities and Exchange Commission. According to Lilly, attorney general offices in Mississippi, Washington D.C., California, Florida, Hawaii, and Nevada are also seeking information on its pricing,

Lilly's blockbuster insulin, Humalog, brings in $3 billion in annual sales. In March, the drugmaker announced its plan to sell an authorized generic version, called n Lispro, for half the cost.

The pricing probe has been ongoing for Lilly. Early this year, members of Congress sent letters to Eli Lilly, Novo Nordisk and Sanofi inquiring about rising insulin prices. The letters requested information from the drugmakers on pricing and the obstacles to providing more affordable insulin, by February 13, 2019.

Read the CNBC coverage